Dr. Mika Michelle Tabata, MD

Dr. Tabata practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Tabata's NPI, 1063040848, was assigned on March 29, 2020. Dr. Tabata graduated from Stanford University School Of Medicine in 2020. Dr. Tabata holds Texas license V1280.

Dr. Tabata's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Tabata's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tabata practices. Vendor and product names are available with a free account.

Dermatology is Dr. Tabata's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Tabata is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Tabata's licenses on file in 3 states: Texas, Pennsylvania and Massachusetts.

CMS data shows 365 Medicare services from Dr. Tabata across 13 procedure codes in 2024, for 149 Medicare patients. Medicare paid $15,231 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 149 Medicare patients who saw Dr. Tabata in 2024. The largest group is 65 to 74, with 81 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tabata's median patient age at 69, with 55% women.

In 2024, Dr. Tabata wrote 83 Medicare Part D claims for 44 patients. 83% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $193,673 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Tabata for performance year 2024, reported as part of a group. Dr. Tabata accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tabata as offering telehealth. CMS counts 212 procedures of skin biopsy by Dr. Tabata, more than 86% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 23 papers to Dr. Tabata, published from 2014 to 2024. 2020 was the busiest year, with 6. The most frequent topics are Nivolumab, Antineoplastic Combined Chemotherapy Protocols and Diagnosis, Differential. Dr. Tabata has published most often in BMJ Case Rep. Dr. Tabata's most frequent co-authors are Bernice Yu Jing Kwong, MD, Kavita Yang Sarin, MD and Steven A. Abrams, MD.

CMS Open Payments shows 3 general payments to Dr. Tabata from 3 drug and device companies in 2024. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $103.

Dr. Tabata graduated from Stanford University School Of Medicine in 2020.

Dr. Tabata is in network with 3 carriers, including Blue Cross Blue Shield of Michigan, Aetna and CMS Medicare. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.